Literature DB >> 2736747

Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3.

A M van der Kraaij1, H G van Eijk, J F Koster.   

Abstract

In this study, we investigated the role of oxygen-derived free radicals and iron in mediating myocardial injury during ischemia and reperfusion. Iron is of special interest because it may enhance tissue injury during ischemia and reperfusion by catalyzing the formation of highly reactive hydroxyl radicals (by modified Haber-Weiss or Fenton reactions). Rat hearts, perfused by the Langendorff method, were subjected to global ischemia (15 minutes at 37 degrees C) and reperfusion. The effects of two iron chelators, 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and 5-hydroxy-2-hydroxymethyl-4-pyrone (kojic acid), and one antioxidant, (+)-cyanidanol-3, on contractile function, coronary flow, lactate dehydrogenase release, and lactate production were studied. The combination of these iron chelators is of special importance because L1 is known to prevent lipid peroxidation, induced by ADP/Fe3+ and NADPH in microsomes, in contrast to kojic acid. We found significant protection of contractile function (apex displacement) during reperfusion with 50 microM L1 and 20 microM (+)-cyanidanol-3 (p less than 0.01, n = 6), whereas no protection was found with 50 microM kojic acid (n = 6). Measurements of lactate dehydrogenase release during reperfusion showed a protective pattern similar to that found for heart contractile function, although 50 microM kojic acid also showed a significantly lower lactate dehydrogenase release during the first 10 minutes of reperfusion. No differences in coronary resistance or lactate release were found between the various groups. Our findings indicate that iron and oxygen-derived free radicals are important in the pathogenesis of postischemic reperfusion injury probably because of the formation of hydroxyl radicals.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2736747     DOI: 10.1161/01.cir.80.1.158

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

1.  Low molecular weight iron and the oxygen paradox in isolated rat hearts.

Authors:  A Voogd; W Sluiter; H G van Eijk; J F Koster
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

2.  Is increased tissue ferritin a risk factor for atherosclerosis and ischaemic heart disease?

Authors:  J F Koster; W Sluiter
Journal:  Br Heart J       Date:  1995-03

Review 3.  Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.

Authors:  J A Barman Balfour; R H Foster
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

4.  Effects of phytic acid on the myoglobin-t-butylhydroperoxide-catalysed oxidation of uric acid and peroxidation of erythrocyte membrane lipids.

Authors:  K M Ko; D V Godin
Journal:  Mol Cell Biochem       Date:  1991-02-27       Impact factor: 3.396

5.  Roles of ferritin and iron in ischemic preconditioning of the heart.

Authors:  Eduard Berenshtein; Boris Vaisman; Chaya Goldberg-Langerman; Nahum Kitrossky; Abraham M Konijn; Mordechai Chevion
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

Review 6.  Metabolic regulation of in vivo myocardial contractile function: multiparameter analysis.

Authors:  M D Osbakken
Journal:  Mol Cell Biochem       Date:  1994 Apr-May       Impact factor: 3.396

7.  The effect of a synthetic hexadentate iron chelator (CP130) and desferrioxamine on rabbit kidneys exposed to cold and warm ischaemia.

Authors:  J D Gower; I J Ambrose; S Manek; J Bright; P S Dobbin; R C Hider; J G Goddard; M S Thorniley; C J Green
Journal:  Agents Actions       Date:  1993-09

Review 8.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 9.  Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.

Authors:  Martin Stěrba; Olga Popelová; Anna Vávrová; Eduard Jirkovský; Petra Kovaříková; Vladimír Geršl; Tomáš Simůnek
Journal:  Antioxid Redox Signal       Date:  2012-10-12       Impact factor: 8.401

10.  Synthesis and antioxidant evaluation of some novel ortho-hydroxypyridine-4-one iron chelators.

Authors:  M Mohammadpour; A Sadeghi; A Fassihi; L Saghaei; A Movahedian; M Rostami
Journal:  Res Pharm Sci       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.